|Day Low/High||0.55 / 0.60|
|52 Wk Low/High||0.46 / 12.49|
Dr. Marnix Bosch, Chief Technical Officer, Presented
Shares and Warrants To Be Cancelled and Reduced; MFN To Be Removed from Contracts
The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.
Progress Also Reported On Additional Nasdaq Compliance Issue
A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.
Leading Experts in Immunotherapies and Oncology From Both the US and Europe
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
New Developments Relating to Phase I and II Trials, Scientific Advisory Board and Nasdaq Compliance
These under-$10 stocks are making big moves higher. Here's how to trade them from here.
TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.
Frank comments and a warning from a doctor supervising pivotal brain cancer vaccine study for Northwest Bio are likely cause of sharp slide in stock price.
Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new March 18th contracts and identified the following put contract of particular interest.
Sees Impact of Global Market Concerns; Reiterates Encouraging Clinical Data
TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.